The mechanism by which it affects the course of tumor aggressiveness is thought to be as follows: BRAF encodes B-RAF, a cytoplasmic serine/threonine kinase (STK) that is involved in constitutive activation of the RAF-MEK-ERK signaling cascade, thereby inhibiting apoptosis and promoting cell proliferation, which ultimately drives tumor growth (9). Here, MARK2 is linked to neoplasm.